Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06785636 | A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC(P300) | recruiting | Phase 1 / Phase 2 | 120 | Pathos AI, Inc.INDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04104776 | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | recruiting | Phase 1 / Phase 2 | 300 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 19, 2026 |
| NCT06966024 | Study of DCC-2812 in Participants With Advanced Genitourinary Cancers | recruiting | Phase 1 | 60 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT05919264 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 619 | Parabilis Medicines, Inc.INDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT06826768 | A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC | recruiting | Phase 1 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05519449 | Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) | recruiting | Phase 1 | 272 | Janux TherapeuticsINDUSTRY | 2 | Aug 13, 2026 | clinicaltrials |
| NCT05613894 | Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer(CaboLu) | recruiting | Phase 1 | 33 | University of UtahOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06236139 | Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 48 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06257693 | Enzalutamide Implants (Enolen) in Patients With Prostate Cancer | recruiting | Phase 1 | 45 | Alessa Therapeutics Inc.INDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06067841 | A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 1 | 140 | Bristol-Myers SquibbINDUSTRY | 3 | Aug 10, 2026 | clinicaltrials |
| NCT07336446 | A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs(ANDROMEDA) | recruiting | Phase 1 / Phase 2 | 300 | AstraZenecaINDUSTRY | 8 | Aug 10, 2026 | clinicaltrials |
| NCT06751329 | A Study of DM002 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 280 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd.INDUSTRY | 2 | Aug 7, 2026 | clinicaltrials |
| NCT05176483 | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors(STELLAR-002) | recruiting | Phase 1 | 1,394 | ExelixisINDUSTRY | 13 | Aug 5, 2026 | clinicaltrials |
| NCT06910657 | IDOV-Immune for Advanced Solid Tumors | recruiting | Phase 1 | 78 | ViroMissile, Inc.INDUSTRY | 2 | Aug 5, 2026 | clinicaltrials |
| NCT06613100 | Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer | recruiting | Phase 1 | 40 | AmgenINDUSTRY | 2 | Jul 31, 2026 | clinicaltrials |
| NCT07288359 | Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 205 | Novartis PharmaceuticalsINDUSTRY | 10 | Jul 30, 2026 | clinicaltrials |
| NCT05113537 | Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer(UPLIFT) | recruiting | Phase 1 / Phase 2 | 30 | Vadim S KoshkinOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06545942 | Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 220 | MOMA TherapeuticsINDUSTRY | 3 | Jul 23, 2026 | clinicaltrials |
| NCT06942104 | Imaging of Solid Tumors Using 18F-TRX | recruiting | Phase 1 | 56 | Rahul AggarwalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06168487 | Telmisartan in Prostate Cancer | recruiting | Phase 1 | 36 | Tyler J CurielOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06066437 | NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial | recruiting | Phase 1 / Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05000294 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | recruiting | Phase 1 / Phase 2 | 29 | University of FloridaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07048314 | Stem Cells for Erectile Dysfunction Post RALP | recruiting | Phase 1 / Phase 2 | 40 | The Methodist Hospital Research InstituteOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT03972657 | A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors | recruiting | Phase 1 / Phase 2 | 345 | Regeneron PharmaceuticalsINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT05413421 | Study of ORIC-944 in Patients With Metastatic Prostate Cancer | recruiting | Phase 1 | 275 | ORIC PharmaceuticalsINDUSTRY | 4 | Jul 9, 2026 | clinicaltrials |
| NCT07103018 | A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)(STRIKE-001) | recruiting | Phase 1 | 144 | K36 Therapeutics, Inc.INDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07689656 | A Clinical Study of [68Ga]Ga-ELI421 Injection PET Imaging in Patients With Prostate Cancer | recruiting | Phase 1 / Phase 2 | 50 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06217822 | First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)(PAnTHA) | recruiting | Phase 1 | 198 | BayerINDUSTRY | 10 | Jul 7, 2026 | clinicaltrials |
| NCT06457919 | A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer | recruiting | Phase 1 / Phase 2 | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07503808 | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types | recruiting | Phase 1 | 150 | IDEAYA BiosciencesINDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07540572 | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors | recruiting | Phase 1 | 160 | IDEAYA BiosciencesINDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05398302 | Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy | recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07441889 | HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006) | recruiting | Phase 1 / Phase 2 | 23 | University of VirginiaOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04886986 | Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer | recruiting | Phase 1 | 42 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05283330 | Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors | recruiting | Phase 1 | 48 | Orano Med Theranostics, SASINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07641049 | Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer(DUAL-NK-PC) | recruiting | Phase 1 | 36 | Beijing BiotechINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04167969 | The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer | recruiting | Phase 1 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | recruiting | Phase 1 | 40 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07600554 | A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate Cancer(SWAP) | recruiting | Phase 1 | 20 | Philogen S.p.A.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06609005 | A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 84 | Shenzhen Ionova Life Sciences Co., Ltd.INDUSTRY | 2 | Jun 4, 2026 | clinicaltrials |
| NCT07198633 | A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer | recruiting | Phase 1 / Phase 2 | 212 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07621692 | Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T | recruiting | Phase 1 | 12 | National Taiwan University HospitalOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07145177 | 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer | recruiting | Phase 1 | 30 | University of California, San FranciscoOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07344311 | A Phase I Trial of A-CAR032 in Participants With mCRPC | recruiting | Phase 1 | 27 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07567521 | A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC | recruiting | Phase 1 / Phase 2 | 90 | C Ray TherapeuticsINDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT06492122 | Study With [225Ac]Ac-FL-020 in mCRPC Participants(ProTACT) | recruiting | Phase 1 | 50 | Full-Life Technologies UK LimitedINDUSTRY | 4 | May 26, 2026 | clinicaltrials |
| NCT06574880 | STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer(STARLiT) | recruiting | Phase 1 / Phase 2 | 45 | Angela Y. Jia, MD PhDOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07189403 | A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 1 | 40 | Daiichi SankyoINDUSTRY | 3 | May 22, 2026 | clinicaltrials |
| NCT07244341 | A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) | recruiting | Phase 1 | 60 | Daiichi SankyoINDUSTRY | 4 | May 15, 2026 | clinicaltrials |
| NCT05413850 | Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection | recruiting | Phase 1 / Phase 2 | 82 | Blue Earth Therapeutics LtdINDUSTRY | 5 | May 14, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 20, 2026source: clinicaltrials